HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)

HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study that tested the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV.. The study enrolled and followed approximately 2,700 HIV-negative men and transgender people who have sex with men in North America, South America, and Switzerland. Report Links: Corey, et. al. 2021. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. New England Journal of Medicine. Web Links: AMP Study Website https://clinicaltrials.gov/ct2/show/NCT02716675